IQVIA (IQV)
(Delayed Data from NYSE)
$219.23 USD
+1.55 (0.71%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $219.01 -0.22 (-0.10%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$219.23 USD
+1.55 (0.71%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $219.01 -0.22 (-0.10%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Zacks News
IQVIA (IQV) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
IQVIA Holdings' (IQV) first-quarter 2024 revenues are likely to have benefited from growth in the Technology and Analytics, and Research and Development segments.
Countdown to IQVIA (IQV) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for IQVIA (IQV), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.
IQVIA Holdings (IQV) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Reasons to Retain IQVIA (IQV) Stock in Your Portfolio Now
by Zacks Equity Research
IQVIA (IQV) is benefitting from its robust capabilities and expansive strategy amid low liquidity and foreign currency exchange rate fluctuation risks.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
IQVIA (IQV) Appreciates 24% in a Year: Here's What to Know
by Zacks Equity Research
IQVIA's (IQV) combined offerings of research and development and commercial services are helping it to develop trusted relationships.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Why Is Tandem Diabetes Care (TNDM) Up 27.4% Since Last Earnings Report?
by Zacks Equity Research
Tandem Diabetes Care (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IQVIA (IQV) Up 5.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IQVIA (IQV) Gains From Global IT Framework, Liquidity Low
by Zacks Equity Research
IQVIA's (IQV) revenue growth is primarily driven by global IT infrastructure and market size amid increasing operating expenses and low liquidity.
Tandem Diabetes Care, Inc. (TNDM) Surges 9.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
CRA International (CRAI) to Post Q4 Earnings: What to Expect?
by Zacks Equity Research
CRA International's (CRAI) fourth-quarter 2023 revenues are likely to have benefitted from improved Forensic Services and Life Sciences performances.
FTI Consulting (FCN) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
FTI Consulting's (FCN) top line benefits from a strong segmental performance in the fourth quarter of 2023.
IQVIA Holdings (IQV) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
IQVIA Holdings' (IQV) revenues increase year over year in fourth-quarter 2023.
Compared to Estimates, IQVIA (IQV) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for IQVIA (IQV) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
IQVIA Holdings (IQV) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
IQVIA (IQV) delivered earnings and revenue surprises of 0.71% and 2.17%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
IQVIA (IQV) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
IQVIA's (IQV) revenues are likely to increase year over year on the back of improving segmental performance.
Stay Ahead of the Game With IQVIA (IQV) Q4 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Evaluate the expected performance of IQVIA (IQV) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Zacks.com featured highlights include NRG Energy, Darden Restaurants, Allison Transmission Holdings and IQVIA Holdings
by Zacks Equity Research
NRG Energy, Darden Restaurants, Allison Transmission Holdings and IQVIA Holdings are part of the Zacks Screen of the Week article.
IQV or IDXX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
IQV vs. IDXX: Which Stock Is the Better Value Option?
4 GARP Stocks to Scoop up for Maximum Returns
by Zacks Equity Research
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. NRG, DRI, ALSN and IQV are some stocks that hold promise.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Here's Why You Should Invest in IQVIA Holdings (IQV) Now
by Zacks Equity Research
IQVIA's (IQV) combined offerings of research and development and commercial services help it to develop trusted relationships.